Korro Bio, Inc.
NASDAQ:KRROBiotechnology
+$1.76 today
- Market cap
- $170.75M
- Beta
- 2.10
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$9.79
Volume 0.16M
Average 0.15M
KRRO Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Korro Bio, Inc.NASDAQ: KRRO
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures declines year over year
Q1 FY2026 capital expenditures of $21K (cash outflow) fell 82.4% year over year, ahead of the -96.6% change in trailing-twelve-month capital expenditures. Sequentially, it fell 75.0% from the prior quarter. Over 3 fiscal years it compounded at -53.7% a year.
Context
- Capital expenditures amounted to 8.1% of revenue in FY2025, down 780.2 pp from a year earlier.
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -82.4% holds above the trailing-twelve-month pace of -96.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (518K) USD
- Year-over-year change
- +97.1%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (518K) | +97.1% |
| FY2024 | 2024-12-31 | (17.9M) | -128.5% |
| FY2023 | 2023-12-31 | (7.84M) | -50.3% |
| FY2022 | 2022-12-31 | (5.21M) | -17.2% |
| FY2021 | 2021-12-31 | (4.45M) | — |
Capital Expenditures vs competitors
How KRRO compares with its peers on the latest reported figures
- KRRO's LTM Mar 2026 capital expenditures of $420K is the 5th largest of the 11 companies compared; the peer median is $234K.
- Its year-over-year change of -96.6% is the lowest of 8, against a peer median of -29.2%.
- Capital expenditures amounts to 10.9% of revenue for KRRO, versus a peer median of 11.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.69M | +140168207.3% | — | 7.8% | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $1.39M | +138.4% | +113.3% | — |
| LTM Mar 2026 | $928K | -8.4% | -10.9% | — | |
| LTM Mar 2026 | $556K | -70.3% | -68.0% | — | |
| LTM Mar 2026 | $420K | -96.6% | -53.7% | 10.9% | |
| LTM Mar 2026 | $362K | -73.2% | -25.8% | — | |
| LTM Mar 2026 | $106K | — | -53.4% | 11.5% | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $78K | — | — | — |
| LTM Mar 2026 | $63K | -29.2% | -72.4% | — | |
| LTM Mar 2026 | $42K | -92.6% | -3.1% | — | |
| LTM Mar 2026 | $32K | — | -55.6% | 88.9% | |
| Peer median (excluding KRRO) | $234K | -29.2% | -39.6% | 11.5% | |
Competitors are the stored peer set for KRRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (21.96M) | (58.03M) | (81.17M) | (83.58M) | (117.26M) |
| Depreciation & Amortization | 1.6M | 2.51M | 3.63M | 3.57M | 3.79M |
| Deferred Income Tax | 0 | (145K) | 0 | 0 | 0 |
| Stock-Based Compensation | 807K | 1.14M | 2.38M | 4.46M | 7.66M |
| Change in Working Capital | 904K | (633K) | 4.28M | 13.59M | (4.43M) |
| Accounts Receivables | 0 | 0 | 0 | (1.7M) | 727K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 56K | 1.76M | 3.1M | (1.34M) | (2.31M) |
| Other Working Capital | 848K | (2.39M) | 1.18M | 16.63M | (2.84M) |
| Other Non-Cash Items | (13.44M) | 1.51M | 3.6M | 1.89M | 31.68M |
| Operating Cash Flow | (32.09M) | (53.65M) | (67.28M) | (60.07M) | (78.56M) |
| Capital Expenditures | (4.45M) | (5.21M) | (7.84M) | (17.9M) | (518K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (35.07M) | (37.21M) | 0 | (146.35M) | (26.19M) |
| Sales of Investments | 0 | 53.49M | 19M | 40.9M | 70.7M |
| Other Investing Activities | 13K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (39.5M) | 11.06M | 11.16M | (123.35M) | 43.99M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 28K | 62K | 117.25M | 67.39M | 685K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2K) | (44K) | 25.05M | 1.97M | 0 |
| Financing Cash Flow | 115.95M | 18K | 187.76M | 69.36M | 685K |
| Effect of Forex Changes | 0 | 0 | 0 | (4K) | 64K |
| Net Change in Cash | 44.35M | (42.57M) | 131.64M | (114.07M) | (33.82M) |
| Free Cash Flow | (36.54M) | (58.86M) | (75.12M) | (77.98M) | (79.08M) |
Korro Bio, Inc.
NASDAQ:KRRO
Intrinsic Alpha fair value
Locked
Current Price
$12.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.